A global pharmaceutical facility clears FDA inspection; three months later CDSCO raises separate objections on the same line for the same product. Two regulators, one facility, one product, two independent conclusions. India's regulatory system does not recognise mutual recognition as an institutional principle. The documentation, timelines, and requirements of one regulator do not accelerate or substitute for another's. What does this reveal about how a multinational should engineer its multi-regulator engagement, and what must each submission actually accomplish?
India's multi-regulator architecture does not recognise mutual recognition as an institutional principle. Each regulator evaluates independently, through its own institutional lens, and neither the documentation nor the clearance issued by one accelerates or substitutes for another. The multinational arriving with a global compliance framework calibrated to its home regulator's architecture discovers this not as an abstract principle but as a file moving through a specific section, in a specific ministry, under a specific officer, at a specific moment in the policy cycle.
In pharmaceuticals and medical devices, the dual compliance architecture between Central Drugs Standard Control Organisation (CDSCO) and the US FDA is the defining challenge. These two regulatory systems do not coordinate. They do not recognise each other's inspections. And they do not evaluate the same facility through the same lens.
The FDA inspection framework operates under current Good Manufacturing Practice (cGMP) regulations codified in 21 CFR Parts 210, 211, and 820, focusing on process validation, data integrity, electronic records compliance under 21 CFR Part 11, and systemic quality management. Observations are issued as FDA 483s, classified by severity and publicly accessible. CDSCO operates under its own inspection protocols that do not recognise FDA compliance as sufficient; the same manufacturing line that received FDA clearance can face CDSCO objections on parameters the FDA did not examine, or examined and approved through a methodology CDSCO does not accept.
The practical consequence is this: a multinational that designs its Indian manufacturing facility to pass FDA inspection may discover that the same facility requires specific modifications to satisfy CDSCO's premises-related requirements under Schedule M; segregation norms for certain product categories, facility layout requirements, and documentation formats that differ from what FDA expects. An India-side compliance strategy that does not account for CDSCO expectations at the facility design stage creates rework, re-inspection, and market access delay. India hosts the largest number of USFDA-compliant plants outside the United States; the domestic regulatory framework these facilities must simultaneously satisfy operates on its own administrative logic.
In electronics and semiconductors, the multi-regulator complexity is structural. A global MNC setting up manufacturing under PLI must simultaneously satisfy MeitY's production thresholds, CBIC's customs classification for imported components, DPIIT's local content requirements under the Make in India order, and state-level environmental and labour clearances. Each operates independently. None defers to the other's assessment.
Apple's India manufacturing trajectory is the defining case study. From zero to over $17 billion in iPhone exports by FY25, Apple built its India manufacturing through Foxconn Hon Hai, Tata Electronics (which acquired Wistron's India operations in 2024), and Pegatron (later acquired by Tata). After Press Note 3 effectively prevented Apple from bringing its existing Chinese component suppliers to India, the company had to rebuild its supplier base from scratch; the supplier count rose from 14 in 2023 to over 40 by CY 2025, with Chinese presence among India-based suppliers below 10%. The India-side strategy could not replicate the China-side supply chain because the regulatory framework prohibited it.
In government procurement, US companies face a layered architecture that is not always visible before the tender is issued. The Global Tender Enquiry (GTE) exemption framework under General Financial Rules (GFR) Rule 161(iv) and Public Procurement (Preference to Make in India) Order (PPPMII) local content thresholds determine whether a foreign manufacturer can participate at all. A multinational firm that has invested in Indian manufacturing but has not tracked where its specific products sit within the exemption architecture may find itself locked out of government tenders despite having a local factory.
The AERB case illustrates a different dimension of institutional experience. A US analytical instruments company selling equipment containing a regulated radioactive source to an Indian industrial customer applied for an Atomic Energy Regulatory Board (AERB) No-Objection Certificate for a spare unit. The application was rejected; not because the spare was unjustified, but because the application did not frame the operational rationale in terms that addressed AERB's specific security concern. The operational logic was sound. The submission did not speak the regulator's language. Submission quality is determined by what the officer needs to see, not by what the applicant wants to say.
For US companies, India is not a single regulatory market. It is a federal, multi-regulator, multi-jurisdiction environment where six agencies may need to concur before a single product reaches a single customer. The companies that manage this successfully are those that understand each regulator's institutional lens, speak each regulator's language, and sequence their engagement so that each approval reinforces rather than constrains the next.